Retacrit | Epoetin Alfa-epbx Injection while Breastfeeding
There are high number of clear evidence that breastfeeding provides best nutrition that you can give to your baby. It is also evident that lactation is good for mothers health as well. Evolution has designed breastfeeding in a way that it caters all nutritional need of your child. However modern medicine is quite new for evolution, that is why mothers body is not well prepared to filter unnecessary chemical found in medicines. It becomes a necessity to figure out which drug is safe and which drug is dangerous for your newborn while nursing. In this article we will understand function of Retacrit | Epoetin Alfa-epbx Injection and its suitability with breastfeeding.

What is Retacrit | Epoetin Alfa-epbx Injection used for?


RETACRIT is an erythropoiesis-stimulating agent (ESA) indicated for: Treatment of anemia due to Chronic Kidney Disease (CKD) in patients on dialysis and not on dialysis (1.1). Zidovudine in patients with HIV-infection (1.2). The effects of concomitant myelosuppressive chemotherapy, and upon initiation, there is a minimum of two additional months of planned chemotherapy (1.3). Reduction of allogeneic RBC transfusions in patients undergoing elective, noncardiac, nonvascular surgery (1.4). Limitations of Use RETACRIT has not been shown to improve quality of life, fatigue, or patient well-being (1.5). RETACRIT is not indicated for use: In patients with cancer receiving hormonal agents, biologic products, or radiotherapy, unless also receiving concomitant myelosuppressive chemotherapy (1.5). In patients with cancer receiving myelosuppressive chemotherapy when the anticipated outcome is cure (1.5). In patients with cancer receiving myelosuppressive chemotherapy in whom the anemia can be managed by transfusion (1.5). In patients scheduled for surgery who are willing to donate autologous blood (1.5). In patients undergoing cardiac or vascular surgery (1.5). As a substitute for RBC transfusions in patients who require immediate correction of anemia (1.5). 1.1 Anemia Due to Chronic Kidney Disease RETACRIT is indicated for the treatment of anemia due to chronic kidney disease (CKD), including patients on dialysis and not on dialysis to decrease the need for red blood cell (RBC) transfusion. 1.2 Anemia Due to Zidovudine in Patients with HIV-infection RETACRIT is indicated for the treatment of anemia due to zidovudine administered at ≤ 4,200 mg/week in patients with HIV-infection with endogenous serum erythropoietin levels of ≤ 500 mUnits/mL. 1.3 Anemia Due to Chemotherapy in Patients with Cancer RETACRIT is indicated for the treatment of anemia in patients with non-myeloid malignancies where anemia is due to the effect of concomitant myelosuppressive chemotherapy, and upon initiation, there is a minimum of two additional months of planned chemotherapy. 1.4 Reduction of Allogeneic Red Blood Cell Transfusions in Patients Undergoing Elective, Noncardiac, Nonvascular Surgery RETACRIT is indicated to reduce the need for allogeneic RBC transfusions among patients with perioperative hemoglobin > 10 to ≤ 13 g/dL who are at high risk for perioperative blood loss from elective, noncardiac, nonvascular surgery. RETACRIT is not indicated for patients who are willing to donate autologous blood pre-operatively. 1.5 Limitations of Use RETACRIT has not been shown to improve quality of life, fatigue, or patient well-being. RETACRIT is not indicated for use: In patients with cancer receiving hormonal agents, biologic products, or radiotherapy, unless also receiving concomitant myelosuppressive chemotherapy. In patients with cancer receiving myelosuppressive chemotherapy when the anticipated outcome is cure. In patients with cancer receiving myelosuppressive chemotherapy in whom the anemia can be managed by transfusion. In patients scheduled for surgery who are willing to donate autologous blood. In patients undergoing cardiac or vascular surgery. As a substitute for RBC transfusions in patients who require immediate correction of anemia.

What are the risk associated with Retacrit | Epoetin Alfa-epbx Injection usage while breastfeeding? What precautions shall I take while using it in breastfeeding?

Retacrit | Epoetin Alfa-epbx Injection safe for breastfeeding
As per our analysis Retacrit | Epoetin Alfa-epbx Injection contains only one ingredient and that is Erythropoietin. We have analyzed Erythropoietin and it seems to be safe to use Erythropoietin while breastfeeding, that means usage of Retacrit | Epoetin Alfa-epbx Injection shall be safe while breastfeeding. Below you can check more details of Erythropoietin usage in breastfeeding. We recommend you to go through provided detailed analysis as below take decision accordingly.

Retacrit | Epoetin Alfa-epbx Injection Breastfeeding Analsys


Erythropoietin while Breastfeeding

Safe

CAS Number: 11096-26-7

Due to a higher molecular weight, excretion into breast milk and absorption are unlikely.


Retacrit | Epoetin Alfa-epbx Injection and breastfeeding

What should I do if I am breastfeeding mother and I am already exposed to Retacrit | Epoetin Alfa-epbx Injection?

As usage of Retacrit | Epoetin Alfa-epbx Injection is mostly safe while breastfeeding hence there should not be any concern. In case of any change in behavior or health of your baby you should inform your health care provider about usage of Retacrit | Epoetin Alfa-epbx Injection else no further action is required.


I am nursing mother and my doctor has suggested me to use Retacrit | Epoetin Alfa-epbx Injection, is it safe?

Usage of Retacrit | Epoetin Alfa-epbx Injection is safe for nursing mothers and baby, No worries.


If I am using Retacrit | Epoetin Alfa-epbx Injection, will my baby need extra monitoring?

No


Who can I talk to if I have questions about usage of Retacrit | Epoetin Alfa-epbx Injection in breastfeeding?

US
National Womens Health and Breastfeeding Helpline: 800-994-9662 (TDD 888-220-5446) 9 a.m. and 6 p.m. ET, Monday through Friday

UK
National Breastfeeding Helpline: 0300-100-0212 9.30am to 9.30pm, daily
Association of Breastfeeding Mothers: 0300-330-5453
La Leche League: 0345-120-2918
The Breastfeeding Network supporter line in Bengali and Sylheti: 0300-456-2421
National Childbirth Trust (NCT): 0300-330-0700

Australia
National Breastfeeding Helpline: 1800-686-268 24 hours a day, 7 days a week

Canada
Telehealth Ontario for breastfeeding: 1-866-797-0000 24 hours a day, 7 days a week

Drug Brands with same Active ingredients